Abstract:Disabilities caused by neurodegeneration have become one of the main causes of mortality in elderly population, with drug distribution to the brain remaining one of the most difficult challenges in the treatment of the central nervous system (CNS) diseases due to the existence of blood–brain barrier. Lectins modified polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) nanoparticles could enhance the drug delivery to the brain following intranasal administration. In this study, basic fibroblast growth factor (bFGF) was entrapped in nanoparticles conjugated with Solanum tuberosum lectin (STL), which selectively binds to N-acetylglucosamine on the nasal epithelial membrane for its brain delivery. The resulting nanoparticles had uniform particle size and negative zeta potential. The brain distribution of the formulations following intranasal administration was assessed using radioisotopic tracing method. The areas under the concentration–time curve of 125I-bFGF in the olfactory bulb, cerebrum, and cerebellum of rats following nasal application of STL modified nanoparticles (STL-bFGF-NP) were 1.79–5.17 folds of that of rats with intravenous administration, and 0.61–2.21 and 0.19–1.07 folds higher compared with intranasal solution and unmodified nanoparticles, respectively. Neuroprotective effect was evaluated using Mirror water maze task in rats with intracerebroventricular injection of β-amyloid25–35 and ibotenic acid. The spatial learning and memory of Alzheimer's disease (AD) rats in STL-bFGF-NP group were significantly improved compared with AD model group, and were also better than other preparations. The results were consistent with the value of choline acetyltransferase activity of rat hippocampus as well as the histological observations of rat hippocampal region. The histopathology assays also confirmed the in vivo safety of STL-bFGF-NP. These results clearly indicated that STL-NP was a promising drug delivery system for peptide and protein drugs such as bFGF to enter the CNS and play the therapeutic role.

[Pharmacokinetics of a Fusion Protein for Human Acidic Fibroblast Growth Factor and Transcriptional Activator Protein in Rat and Its Penetration Across Blood-Brain Barrier].

Evaluation of the Safety and Brain-Related Tissues Distribution Characteristics of Tat-Hafgf Via Intranasal Administration

Intranasal Administration of TAT-haFGF14–154 Attenuates Disease Progression in a Mouse Model of Alzheimer’s Disease

Pharmacokinetic Modelling of Human Recombinant Protein, p75ECD-Fc: A Novel Therapeutic Approach for Treatment of Alzheimer’s Disease, in Serum and Tissue of Sprague Dawley Rats

High-level Expression and Purification of Tat-haFGF19-154

Construction, expression, purification and neuroprotective activity of TAT-FGF21 fusion protein

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

TAT-HSA-α-MSH fusion protein with extended half-life inhibits tumor necrosis factor-α in brain inflammation of mice

Transthyretin-Penetratin: A Potent Fusion Protein Inhibitor Against Alzheimer's Amyloid-β Fibrillogenesis with High Blood Brain Barrier Crossing Capability.

Neuroprotective Effect of TAT-14-3-3ε Fusion Protein against Cerebral Ischemia/Reperfusion Injury in Rats

Neuroprotective Effect Of Tat-14-3-3 Epsilon Fusion Protein Against Cerebral Ischemia/Reperfusion Injury In Rats

Intranasal TAT-haFGF Improves Cognition and Amyloid-β Pathology in an AβPP/PS1 Mouse Model of Alzheimer’s Disease

Intranasal Nanoparticles of Basic Fibroblast Growth Factor for Brain Delivery to Treat Alzheimer'S Disease

Cell-penetrating peptide TAT-mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats

[Neuroprotection of a Neotype Transactivating-Brain-derived Neurotrophic Factor Fusion Protein with Penetrating Activity of Blood-Brain Barrier].

Construction of Vector Ptat-Bdnf and Expression of Fusion Protein

TAT Protein Transduction Domain Mediates Transmembrane Delivery of BCR/ABL Fusion Protein into Tissue Cells of Mice in Vivo

Tat-Hafgf(14-154) Upregulates Adam10 To Attenuate The Alzheimer Phenotype Of App/Ps1 Mice Through The Pi3k-Creb-Ire1 Alpha/Xbp1 Pathway

Receptor-Mediated Abeta Amyloid Antibody Targeting to Alzheimer’s Disease Mouse Brain

TAT Protein Transduction Domain-Mediated the BCR/ABL Fusion Protein Passing Through the Blood-Brain Barrier of the Mouse in Vivo

TAT Protein Transduction Domain Mediates Transmembrane Delivery of EGFP into Tissue Cells of Mice in Vivo